Introduction
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
Information is being updated
You need to login to view information
Charter capital
Business Size and Operations
Company Size
Total Assets
| A10 (Bellow 100 B) | A9 (100 - 200 B) | A8 (200 - 400 B) | A7 (400 - 600 B) | A6 (600 - 800 B) |
| A5 (800 - 1000 B) | A4 (1000 - 1500 B) | A3 (1500 - 2000 B) | A2 (2000 - 2500 B) | A1 (Above 2500 B) |
Owner’s Equity
| E10 (Bellow 100 B) | E9 (100 - 200 B) | E8 (200 - 400 B) | E7 (400 - 600 B) | E6 (600 - 800 B) |
| E5 (800 - 1000 B) | E4 (1000 - 1500 B) | E3 (1500 - 2000 B) | E2 (2000 - 2500 B) | E1 (Above 2500 B) |
Business Activities
Revenue
| R10 (Bellow 100 B) | R9 (100 - 200 B) | R8 (200 - 400 B) | R7 (400 - 600 B) | R6 (600 - 800 B) |
| R5 (800 - 1000 B) | R4 (1000 - 1500 B) | R3 (1500 - 2000 B) | R2 (2000 - 2500 B) | R1 (Above 2500 B) |
Number of employee
| L10 (Bellow 100 Peoples) | L9 (100 - 200 Peoples) | L8 (200 - 400 Peoples) | L7 (400 - 600 Peoples) | L6 (600 - 800 Peoples) |
| L5 (800 - 1000 Peoples) | L4 (1000 - 1500 Peoples) | L3 (1500 - 2000 Peoples) | L2 (2000 - 2500 Peoples) | L1 (Above 2500 Peoples) |
Company’s Market Position
Profitability within the Industry
Return on Total Assets (ROA)
| Bottom 25% | 25%-m | m-25% | Top 25% |
Return on Equity (ROE)
Net Profit Margin (ROS)
Current Ratio
| Bottom 25% | 25%-m | m-25% | Top 25% |
Total asset turnover
| Bosttom 25% | 25%-m | m-25% | Top 25% |